[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100481049":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":38,"locations":45,"responsibleParty":169,"collaborators":171,"id":175,"slug":51,"hasResults":176,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":176,"sex":182,"minAge":183,"maxAge":51,"enrollmentInfo":184,"targetDuration":51,"studyType":187,"phases":188,"briefSummary":190,"conditions":191,"keywords":51,"overallStatus":48,"whyStopped":51,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":205},{"fullName":5,"class":6},"Ottawa Hospital Research Institute","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"XPERIENCE Advanced Surgical Irrigation","EXPERIMENTAL","Patients will receive the XPERIENCE Advanced Surgical Irrigation prior to wound closure.",[13],"Device: XPERIENCE Advanced Surgical Irrigation",{"label":15,"type":16,"description":17,"interventionNames":18},"Dilute Betadine","ACTIVE_COMPARATOR","Patients will receive Dilute Betadine solution prior to wound closure.",[19],"Device: Dilute Betadine",[21,27],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","The patient will undergo THA, TKA, or HR with irrigation of the deep wound prior to fascial closure consisting of XPERIENCE Advanced Surgical Irrigation (XP). XP solution will be applied prior to fascial closure and left to soak for up to 3 minutes. Remaining product will be suctioned away throughout the procedure. No rinsing should take place after irrigation and surgical site will be closed according to site standard operating procedures.",[9],[26],"XP",{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":30},"The patient will undergo THA, HR or TKA with irrigation of the deep wound prior to fascial closure consisting of Dilute Betadine (DB). DB concentration will be standardized at 0.3% povidone-iodine. DB will be prepared by combining 30 mL of sterile 10% povidone-iodine (from a sterile catheter pack) with 1 L of 0.9% saline in a sterile splash basin. Solution will be left to soak for up to 3 minutes and remaining povidone-iodine solution will be suctioned away. Area will then be rinsed with 1L of normal saline. Surgical site will be closed according to site standard operating procedures.",[15],[31,32],"DB","Providone-Iodine",[34],{"name":35,"affiliation":36,"role":37},"Simon Garceau, MD","The Ottawa Hospital","PRINCIPAL_INVESTIGATOR",[39],{"name":40,"role":41,"phone":42,"phoneExt":43,"email":44},"Sanjula Costa","CONTACT","613-737-8899","72640","scosta@ohri.ca",[46,66,83,94,110,122,142,153],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"University of British Columbia","RECRUITING","Vancouver","British Columbia",null,"Canada","CA",{"type":55,"coordinates":56},"Point",[57,58],-123.11934,49.24966,{"lat":58,"lon":57},[61,64],{"name":62,"role":41,"phone":51,"phoneExt":51,"email":63},"Kelsey Lee","kelsey.lee@vch.ca",{"name":65,"role":37,"phone":51,"phoneExt":51,"email":51},"Michael Neufeld, MD",{"facility":67,"status":48,"city":68,"state":69,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"London Health Sciences Center","London","Ontario",{"type":55,"coordinates":71},[72,73],-81.23304,42.98339,{"lat":73,"lon":72},[76,81],{"name":77,"role":41,"phone":78,"phoneExt":79,"email":80},"Abbigail Allen","519-685-8500","37843","Abbigail.Allen@lhsc.on.ca",{"name":82,"role":37,"phone":51,"phoneExt":51,"email":51},"Brent Lanting, MD",{"facility":36,"status":48,"city":84,"state":69,"zip":85,"country":52,"countryCode":53,"cosmosGeoPoint":86,"geoPoint":90,"contacts":91},"Ottawa","K1H 8L6",{"type":55,"coordinates":87},[88,89],-75.69812,45.41117,{"lat":89,"lon":88},[92,93],{"name":40,"role":41,"phone":42,"phoneExt":43,"email":44},{"name":35,"role":37,"phone":51,"phoneExt":51,"email":51},{"facility":95,"status":48,"city":96,"state":69,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"Humber River Health","Toronto",{"type":55,"coordinates":98},[99,100],-79.39864,43.70643,{"lat":100,"lon":99},[103,108],{"name":104,"role":41,"phone":105,"phoneExt":106,"email":107},"Michele Petrovic","416-242-1000","81263","MPetrovic@hrh.ca",{"name":109,"role":37,"phone":51,"phoneExt":51,"email":51},"Sebastian Rodriguez-Elizalde, MD",{"facility":111,"status":48,"city":96,"state":69,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":112,"geoPoint":114,"contacts":115},"St. Joseph's Health Centre",{"type":55,"coordinates":113},[99,100],{"lat":100,"lon":99},[116,120],{"name":117,"role":41,"phone":118,"phoneExt":51,"email":119},"Carlos Fernando","416-864-6060 x 46969","Carlos.Fernando@unityhealth.to",{"name":121,"role":37,"phone":51,"phoneExt":51,"email":51},"George Vincent, MD",{"facility":123,"status":48,"city":124,"state":125,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":126,"geoPoint":130,"contacts":131},"Hôpital Maisonneuve-Rosemont","Montreal","Quebec",{"type":55,"coordinates":127},[128,129],-73.58781,45.50884,{"lat":129,"lon":128},[132,137,140],{"name":133,"role":41,"phone":134,"phoneExt":135,"email":136},"Serge Marquis","514-252-3400","5701","smarquis.hmr@ssss.gouv.qc.ca",{"name":138,"role":41,"phone":51,"phoneExt":51,"email":139},"Janie Barry","jbarry.hmr@ssss.gouv.qc.ca",{"name":141,"role":37,"phone":51,"phoneExt":51,"email":51},"Alexandre Benny, MD",{"facility":143,"status":48,"city":124,"state":125,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":144,"geoPoint":146,"contacts":147},"Jewish General Hospital",{"type":55,"coordinates":145},[128,129],{"lat":129,"lon":128},[148,151],{"name":149,"role":41,"phone":51,"phoneExt":51,"email":150},"Laura Epure","laura.epure@mcgill.ca",{"name":152,"role":37,"phone":51,"phoneExt":51,"email":51},"John Antoniou, MD",{"facility":154,"status":48,"city":155,"state":125,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":156,"geoPoint":160,"contacts":161},"CHU de Quebec-Université Laval","Québec",{"type":55,"coordinates":157},[158,159],-71.21454,46.81228,{"lat":159,"lon":158},[162,167],{"name":163,"role":41,"phone":164,"phoneExt":165,"email":166},"Sylvie Turmel","418-525-4444","66175","turmel.sylvie@chudequebec.ca",{"name":168,"role":37,"phone":51,"phoneExt":51,"email":51},"Etienne Belzile, MD",{"type":170,"investigatorFullName":51,"investigatorTitle":51,"investigatorAffiliation":51,"oldNameTitle":51,"oldOrganization":51},"SPONSOR",[172],{"name":173,"class":174},"OsteoRemedies, LLC","INDUSTRY","100481049",false,"NCT05543941","Evaluating XPERIENCE™ Advanced Surgical Irrigation","Evaluating XPERIENCE™ Advanced Surgical Irrigation on Risk of Periprosthetic Joint Infection: A Multicenter Randomized Controlled Trial","XPERIENCE","Inclusion Criteria:\n\n1. Male and female patients aged 18 years or older\n2. Diagnosis of osteoarthritis, inflammatory arthritis, osteonecrosis, or post-traumatic arthritis to the affected joint.\n3. Primary TKA, THA, and HR\n4. Subjects receiving both cemented or uncemented orthopaedic implants\n5. Willing and able to sign written consent, follow study protocol and attend follow-up\n\nExclusion Criteria:\n\n1. Inability or refusal to sign informed consent form\n2. Non-English or French speaking, and no licensed translator, family member or substitute decision maker available.\n3. Prior arthroplasty procedure to the affected joint\n4. Procedures involving solid HA implants\n5. Oncologic diagnosis to the affected joint.\n6. Non-TKA, THA or HR prosthesis (i.e., hemiarthroplasty, unicompartmental arthroplasty etc.)\n7. Allergy to any of the components of XP Advanced Surgical Irrigation\n8. Allergy to iodine\n9. Presence of concurrent active infection, primary immunodeficiency, history of uncontrolled HIV (CD4 count \\\u003C200 cells\u002FuL), treatment with immunomodulatory medications for malignancy or autoimmune disease (with exception to inflammatory arthritis), chronic glucocorticosteroid use (≥20 mg of prednisone daily for at least 1 month with another cause of immunosuppression), and solid organ and\u002For bone marrow transplantation.\n10. History of septic arthritis to the affected joint within two years of surgery(1).\n11. History of steroid injection to the affected joint within the three months preceding surgery.\n12. Simultaneous bilateral total joint arthroplasty","ALL","18 Years",{"count":185,"type":186},7600,"ESTIMATED","INTERVENTIONAL",[189],"NA","A prospective, multi-center, double-arm, parallel, interventional, randomized, controlled clinical trial to assess the rate of periprosthetic joint infection (PJI) in patients undergoing primary total knee arthroplasty (TKA), total hip arthroplasty (THA) or hip resurfacing (HR) with XPERIENCE™ (XP) Advanced Surgical Irrigation versus dilute Betadine (DB).",[192,193,194,195],"Hip Osteoarthritis","Hip Arthritis","Knee Osteoarthritis","Knee Arthritis","2026-05-25",{"date":198,"type":199},"2026-05-28","ACTUAL",{"date":201,"type":199},"2023-04-01",{"date":203,"type":186},"2027-12-31",{"name":5,"class":6},8]